TRAF3 and neoplasm: Collectively, the present results suggest that when tumor-derived mutant TRAF3 becomes resistant to receptor-mediated degradation, stabilization of cellular NIK levels is controlled by TRAF3 degradation-independent mechanisms to regulate NF-κB2 activation in B cells.